small molecule

VOXZOGO

VOSORITIDE

Loss of exclusivityJuly 2042latest FDA-listed patent expiry

CompanyBiomarin Pharmaceutical →See this company's full patent-cliff portfolio

Drug detail

Brand name	VOXZOGO
Active ingredient	VOSORITIDE
Strength	0.4MG/VIAL
Dosage form	POWDER
Route	SUBCUTANEOUS
Modality	Small molecule
FDA approval	November 2021
Marketing status	RX

Listed patents

Patent	Expires	Type
12233106	July 2042	use U-3927
11590204	August 2036	product
12514906	August 2036	product
11911446	August 2036	use U-3927
10646550	August 2036	product
9907834	August 2036	product
8198242	June 2035	substance, product
RE48267	May 2030	use U-3927

Regulatory exclusivity

Code	Expires
ODE-449	October 2030
ODE-387	November 2028
NCE	November 2026
NPP	October 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Biomarin Pharmaceutical